Analysis of the incidence of community-acquired pneumonia and acute otitis media in children during the first four years of life in different age groups vaccinated with pneumococcal 13-valent vaccine Prevenar
Objective: to analyze the incidence of community-acquired pneumonia and acute otitis media in children during the first four years of life in different age groups vaccinated with pneumococcal 13-valent vaccine Prevenar.Materials and methods: medical records of 590 children aged 1 to 5 years were ana...
| Published in: | Медицинский вестник Юга России |
|---|---|
| Main Authors: | S. A. Pyrkova, L. P. Voronina, M. E. Kuzin, V. V. Cherepova, E. A. Polunina |
| Format: | Article |
| Language: | English |
| Published: |
State Budget Educational Institute of Higher Professional Education, Rostov State Medical University, Ministry Health of Russian Federation
2019-10-01
|
| Subjects: | |
| Online Access: | https://www.medicalherald.ru/jour/article/view/896 |
Similar Items
Assessment of Safety, Immunogenicity and Preventive Efficacy of Prevenar-13 in Children with Bronchopulmonary Dysplasia
by: E. S. Zubova, et al.
Published: (2018-04-01)
by: E. S. Zubova, et al.
Published: (2018-04-01)
Serotype Replacement after Introduction of 10-Valent and 13-Valent Pneumococcal Conjugate Vaccines in 10 Countries, Europe
by: Germaine Hanquet, et al.
Published: (2022-01-01)
by: Germaine Hanquet, et al.
Published: (2022-01-01)
Cost-effectiveness evaluation of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine for children in Taiwan
by: Chun-Yi Lu, et al.
Published: (2020-08-01)
by: Chun-Yi Lu, et al.
Published: (2020-08-01)
EXPERIENCE OF APPLICATION AND SAFETY ASSESSMENT OF THE 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN UNDER-5 CHILDREN
by: M. V. Fedoseenko, et al.
Published: (2014-09-01)
by: M. V. Fedoseenko, et al.
Published: (2014-09-01)
Choice of optimal vaccination tactics against pneumococcal infection from immunological and clinical standpoints in patients with chronic obstructive pulmonary disease
by: A D Protasov, et al.
Published: (2016-05-01)
by: A D Protasov, et al.
Published: (2016-05-01)
Uptake of 13-Valent Pneumococcal Conjugate Vaccine among US Adults Aged 19 to 64 Years with Immunocompromising Conditions
by: Jeffrey Vietri, et al.
Published: (2020-01-01)
by: Jeffrey Vietri, et al.
Published: (2020-01-01)
A cost-effectiveness analysis of the 13-valent pneumococcal conjugated vaccine and the 23-valent pneumococcal polysaccharide vaccine among Thai older adult
by: Thundon Ngamprasertchai, et al.
Published: (2023-06-01)
by: Thundon Ngamprasertchai, et al.
Published: (2023-06-01)
Decrease of Pneumococcal Community-Acquired Pneumonia Hospitalization and Associated Complications in Children after the Implementation of the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) in Taiwan
by: Ching-Fen Shen, et al.
Published: (2021-09-01)
by: Ching-Fen Shen, et al.
Published: (2021-09-01)
Disparities in uptake of 13-valent pneumococcal conjugate vaccine among older adults in the United States
by: John M. McLaughlin, et al.
Published: (2019-04-01)
by: John M. McLaughlin, et al.
Published: (2019-04-01)
Pneumococcal conjugate 7-valent vacciPNEUMOCOCCAL CONJUGATE 7-VALENT VACCINE IN CHILDREN. REGIONAL EXPERIENCEne in children. Regional experience
by: N. L. Chernaya, et al.
Published: (2012-02-01)
by: N. L. Chernaya, et al.
Published: (2012-02-01)
Changes in Childhood Pneumonia Hospitalizations by Race and Sex Associated with Pneumococcal Conjugate Vaccines
by: Andrew D. Wiese, et al.
Published: (2016-06-01)
by: Andrew D. Wiese, et al.
Published: (2016-06-01)
PHARMACOECONOMIC ASSESSMENT OF 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN IMMUNIZATION OF CHILDREN IN RUSSIAN FEDERATION
by: A. V. Rudakova, et al.
Published: (2014-01-01)
by: A. V. Rudakova, et al.
Published: (2014-01-01)
Clinical Efficacy of Pneumococcal Conjugate 13-valent Vaccine in Young Children
by: S. M. Kharit, et al.
Published: (2016-12-01)
by: S. M. Kharit, et al.
Published: (2016-12-01)
Vaccination in Adults with 23 valent Pneumococcal Polysaccharide Vaccine –ABC: Awareness, Benefits and Clinical Aspects
by: Salil Bendre, et al.
Published: (2024-02-01)
by: Salil Bendre, et al.
Published: (2024-02-01)
Vaccination in Adults with 23 valent Pneumococcal Polysaccharide Vaccine –ABC: Awareness, Benefits and Clinical Aspects
by: Salil Bendre, et al.
Published: (2024-02-01)
by: Salil Bendre, et al.
Published: (2024-02-01)
Epidemiological and etiological characteristics of community-acquired pneumonia in conscripts in the modern period. Comparative evaluation of the effectiveness of pneumococcal vaccines
by: P. V. Kulikov, et al.
Published: (2019-05-01)
by: P. V. Kulikov, et al.
Published: (2019-05-01)
Pharmacoeconomic aspects of vaccination against Pneumococcal Infection in Russia
by: A. V. Rudakova, et al.
Published: (2014-09-01)
by: A. V. Rudakova, et al.
Published: (2014-09-01)
Cost-effectiveness of 20-valent pneumococcal conjugate vaccine compared with 23-valent pneumococcal polysaccharide vaccine among adults in a Norwegian setting
by: Mikkelsen Malene B, et al.
Published: (2023-08-01)
by: Mikkelsen Malene B, et al.
Published: (2023-08-01)
The Experience of Vaccination of a Patient With Juvenile Idiopathic Arthritis With Frequent Respiratory Infections With a Pneumococcal 13-Valent Conjugate Vaccine During Methotrexate Therapy
by: Margarita A. Soloshenko, et al.
Published: (2017-10-01)
by: Margarita A. Soloshenko, et al.
Published: (2017-10-01)
Persistence of antibodies 1 year after sequential administration of the 13-valent pneumococcal conjugate vaccine and the 23-valent pneumococcal polysaccharide vaccine in adults
by: Beate Schmoele-Thoma, et al.
Published: (2019-03-01)
by: Beate Schmoele-Thoma, et al.
Published: (2019-03-01)
Late onset of injection site reactions after vaccination with the 13-valent pneumococcal conjugate vaccine in adult study populations
by: Christine Juergens, et al.
Published: (2018-08-01)
by: Christine Juergens, et al.
Published: (2018-08-01)
Safety of simultaneous vaccination of 13-valent pneumococcal polysaccharide conjugate vaccine with other vaccines in Shanghai from 2017 to 2021
by: YANG Shoufei, et al.
Published: (2022-08-01)
by: YANG Shoufei, et al.
Published: (2022-08-01)
PNEUMOCOCCAL INFECTION VACCINAL PREVENTION EFFICACY IN CHILDREN USING PNEUMOCOCCAL CONJUGATED 7-VALENT VACCINE
by: N. L. Chernaya, et al.
Published: (2013-01-01)
by: N. L. Chernaya, et al.
Published: (2013-01-01)
Vaccine effectiveness of the pneumococcal polysaccharide and conjugated vaccines in elderly and high-risk populations in preventing invasive pneumococcal disease: a systematic search and meta-analysis
by: Melina Gade Sikjær, et al.
Published: (2023-01-01)
by: Melina Gade Sikjær, et al.
Published: (2023-01-01)
Clinical and Bacteriological Analysis of Pediatric Pneumococcal Meningitis after 13-Valent Pneumococcal Conjugate Vaccine Introduction in Japan
by: Erika Kurihara, et al.
Published: (2022-04-01)
by: Erika Kurihara, et al.
Published: (2022-04-01)
Immunogenicity of pneumococcal vaccination in HIV infected individuals: A systematic review and meta-analysis
by: Hannah M.Garcia Garrido, et al.
Published: (2020-12-01)
by: Hannah M.Garcia Garrido, et al.
Published: (2020-12-01)
The Effect of Different Regimens of Vaccination against Pneumococcal Infection on the Clinical Course of Chronic Obstructive Pulmonary Disease: Focus on Changes in Sputum Microorganism Population
by: M. P. Kostinov, et al.
Published: (2021-08-01)
by: M. P. Kostinov, et al.
Published: (2021-08-01)
Effectiveness of 13-valent pneumococcal polysaccharide conjugate vaccine on community-acquired pneumonia: a retrospective cohort study among young children in Suzhou city
by: Zhao-jin LI, et al.
Published: (2022-11-01)
by: Zhao-jin LI, et al.
Published: (2022-11-01)
Vaccination pattern of the 23-valent pneumococcal polysaccharide vaccine (PPV23) in Hangzhou, China: a coverage and adverse events following immunization of different age groups
by: Yan Liu, et al.
Published: (2021-01-01)
by: Yan Liu, et al.
Published: (2021-01-01)
Empyema due to Streptococcus Pneumoniae Serotype 9V in a Child Immunized with 13-Valent Conjugated Pneumococcal Vaccine
by: Murat Sütçü, et al.
Published: (2017-02-01)
by: Murat Sütçü, et al.
Published: (2017-02-01)
Analysis of 13-valent pneumococcal polysaccharide conjugate vaccine among children born in Hangzhou from 2017 to 2021
by: Xinren Che, et al.
Published: (2023-05-01)
by: Xinren Che, et al.
Published: (2023-05-01)
13-valent Pneumococcal Conjugate Vaccine and Haemophilus Influenzae-Tetanus Toxoid Conjugate Vaccine in Patient with Systemic Juvenile Idiopathic Arthritis Receiving Tocilizumab: Clinical Case
by: Ekaterina I. Alekseeva, et al.
Published: (2019-09-01)
by: Ekaterina I. Alekseeva, et al.
Published: (2019-09-01)
Streptococcus pneumoniae Serotype 12F-CC4846 and Invasive Pneumococcal Disease after Introduction of 13-Valent Pneumococcal Conjugate Vaccine, Japan, 2015–2017
by: Satoshi Nakano, et al.
Published: (2020-11-01)
by: Satoshi Nakano, et al.
Published: (2020-11-01)
Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccine on Invasive Pneumococcal Disease in Greenland
by: Kristiana Alexandrova Nikolova, et al.
Published: (2021-10-01)
by: Kristiana Alexandrova Nikolova, et al.
Published: (2021-10-01)
Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine administered in a prime-boost regimen among Chinese infants: a randomized, double blind phase III clinical trial
by: Wenjuan Wang, et al.
Published: (2022-01-01)
by: Wenjuan Wang, et al.
Published: (2022-01-01)
Surveillance of adverse events following immunization of 13-valent pneumococcal conjugate vaccine among infants, in Zhejiang province, China
by: Yu Hu, et al.
Published: (2022-01-01)
by: Yu Hu, et al.
Published: (2022-01-01)
Experience of Vaccination of a Patient with Systemic Juvenile Idiopathic Arthritis (sJIA) with a 13-Valent Pneumococcal Conjugate Vaccine, prior to the Appointment of Therapy with Tocilizumab, an Anti-IL-6-Receptor Monoclonal Antibody
by: Daria D. Vankova, et al.
Published: (2018-10-01)
by: Daria D. Vankova, et al.
Published: (2018-10-01)
Immunogenicity of 23-Valent Pneumococcal Vaccine in Children with Systemic Lupus Erythematosus
by: Soheila Alyasin, et al.
Published: (2016-09-01)
by: Soheila Alyasin, et al.
Published: (2016-09-01)
Immunogenicity, Safety, and Clinical Effectiveness of the 23-Valent Pneumococcal Polysaccharide Vaccine in Patients With Spondyloarthritis (Preliminary Data)
by: M. M. Baranova, et al.
Published: (2022-04-01)
by: M. M. Baranova, et al.
Published: (2022-04-01)
Cost-effectiveness analysis of domestic 13-valent pneumococcal conjugate vaccine for children under 5 years of age in mainland China
by: Caixia Wang, et al.
Published: (2021-07-01)
by: Caixia Wang, et al.
Published: (2021-07-01)
Similar Items
-
Assessment of Safety, Immunogenicity and Preventive Efficacy of Prevenar-13 in Children with Bronchopulmonary Dysplasia
by: E. S. Zubova, et al.
Published: (2018-04-01) -
Serotype Replacement after Introduction of 10-Valent and 13-Valent Pneumococcal Conjugate Vaccines in 10 Countries, Europe
by: Germaine Hanquet, et al.
Published: (2022-01-01) -
Cost-effectiveness evaluation of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine for children in Taiwan
by: Chun-Yi Lu, et al.
Published: (2020-08-01) -
EXPERIENCE OF APPLICATION AND SAFETY ASSESSMENT OF THE 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN UNDER-5 CHILDREN
by: M. V. Fedoseenko, et al.
Published: (2014-09-01) -
Choice of optimal vaccination tactics against pneumococcal infection from immunological and clinical standpoints in patients with chronic obstructive pulmonary disease
by: A D Protasov, et al.
Published: (2016-05-01)
